SDF1 neutralizing antibody

An SDF1 neutralizing antibody (also known as an anti-CXCL12 antibody) is a therapeutic modality designed to bind and neutralize stromal cell-derived factor 1 (SDF-1, or CXCL12), a homeostatic chemokine that plays a critical role in cell migration, hematopoiesis, angiogenesis, and tumor microenvironment regulation. By blocking the interaction of CXCL12 with its receptors, CXCR4 and ACKR3 (CXCR7), these antibodies inhibit downstream signaling pathways (such as MAPK/ERK and PI3K/Akt) that promote tumor cell survival, metastasis, and immunosuppression. SDF1 neutralizing antibodies are being investigated in preclinical and clinical settings for various indications, including oncology (to disrupt the tumor-supportive niche and enhance immunotherapy), inflammatory diseases, and pathological hair loss conditions like androgenic alopecia and alopecia areata.

Other names

CXCL12 neutralizing antibodyCXCL-12 neutralizing antibodyCXCL 12 neutralizing antibodySDF-1 neutralizing antibodySDF1 neutralizing antibodySDF 1 neutralizing antibodyanti-CXCL12 antibodyanti-CXCL-12 antibodyanti-CXCL 12 antibodyanti-CXCL12 monoclonal antibodyanti-CXCL-12 monoclonal antibodyanti-CXCL 12 monoclonal antibodyanti-SDF-1 antibodyanti-SDF1 antibodyanti-SDF 1 antibodyanti-SDF-1 monoclonal antibodyanti-SDF1 monoclonal antibodyanti-SDF 1 monoclonal antibody